comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children

The purpose of the present study is to compare efficacy and safety of buccal midazolam with intravenous diazepam in control of seizures in Iranian children. This is a randomized clinical trial. 92 patients with acute seizures, ranging from 6 months to 14 years were randomly assigned to receive either buccal midazolam [32 cases] or intravenous diazepam [60 cases] at the emergency department of a children's hospital. The primary outcome of this study was cessation of visible seizure activity within 5 minutes from administration of the first dosage. The second dosage was used in case the seizure remained uncontrolled 5 minutes after the first one. In the midazolam group, 22 [68.8%] patients were relieved from seizures in 10 minutes. Meanwhile, diazepam controlled the episodes of 42 [70%] patients within 10 minutes. The difference was, however, not statistically significant [P=0.9]. The mean time required to control the convulsive episodes after administration of medications was not statistically significant [P=0.09]. No significant side effects were observed in either group. Nevertheless, the risk of respiratory failure in intravenous diazepam is greater than in buccal midazolam. Buccal midazolam is as effective as and safer than intravenous diazepam in control of seizures